News

Gilead acquires gamgertamig from Lakefront for $1.675B upfront to pursue rapid B cell depletion in severe autoimmune diseases.

Photocure acquires AssureMDx Bladder Cancer Test for $30.5M, with $13.75M tied to Medicare reimbursement and regulatory milestones through 2029.

MEDIPOST secures FDA agreement for single Phase 3 Study of CARTISTEM, its stem cell treatment for knee osteoarthritis, leveraging...

Biomea Fusion partners with University of Leicester to test icovamenib for obesity, focusing on lean mass preservation alongside semaglutide...

Regeneron expands CytomX partnership on conditional bispecifics to $4B, targeting solid tumors with masked T-cell engagers.

Telix and United Imaging partner to integrate TLX101-Px theranostics with scanner hardware and AI workflows ahead of the September...

Nipocalimab shows sustained SLE response in J&J Phase 2 study, with 58.2% response rate in autoantibody-positive patients at Week...

FDA's PRC2 Class Risk ruling halts Fulcrum's pociredir development in sickle cell disease, effectively blocking the entire mechanism class.

Outlook Therapeutics resubmits LYTENAVA Bevacizumab to FDA with a 60-day review timeline after successful appeal of prior rejection.

Jasper Therapeutics explores strategic alternatives for briquilimab program amid funding constraints and Phase 2b/3 trial execution risks.